ReviewF1000prime reports2014
Cell-mediated immunity to human CMV infection: a brief overview.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda.Nature communications · 2021Article
- Cytomegalovirus in Haematological Tumours.Frontiers in immunology · 2021Review
- Immune Landscape of CMV Infection in Cancer Patients: From "Canonical" Diseases Toward Virus-Elicited Oncomodulation.Frontiers in immunology · 2021Review
- Deciphering the Immunological Phenomenon of Adaptive Natural Killer (NK) Cells and Cytomegalovirus (CMV).International journal of molecular sciences · 2020Review
- Article
- Review
- Clinical characteristics of cytomegalovirus gastritis: A retrospective study from a tertiary medical center.Medicine · 2020Article
- Article
- PTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation.Frontiers in immunology · 2019Article
- SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis.Frontiers in immunology · 2019Review
- Assessment of the T-SPOT.CMV interferon-γ release assay in renal transplant recipients: A single center cohort study.PloS one · 2018Observational
- T-cell responses to KSHV infection: a systematic approach.Oncotarget · 2017Article
- Natural killer cells attenuate cytomegalovirus-induced hearing loss in mice.PLoS pathogens · 2017Article
- Impact of Antibodies and Strain Polymorphisms on Cytomegalovirus Entry and Spread in Fibroblasts and Epithelial Cells.Journal of virology · 2017Article
- T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies.Frontiers in immunology · 2017Review
- Article
- The silent war of CMV in aging and HIV infection.Mechanisms of ageing and development · 2016Review
- Evaluation of T Cell Immunity against Human Cytomegalovirus: Impact on Patient Management and Risk Assessment of Vertical Transmission.Journal of immunology research · 2016Review
- Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner.Frontiers in microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cellular immune response to human cytomegalovirus (HCMV) has different components originating from both the adaptive and innate immune systems. There is a significant global interest in understanding how the immune system keeps HCMV under control, in particular with a view to situations where HCMV infection causes severe damage. Such settings include HIV infection, transplantation, and maybe most importantly perinatal medicine, HCMV being a major cause of sometimes catastrophic birth defects. The development of an active HCMV vaccine has proven very difficult but some recent successes raise hope that this might be available in the future. However, adoptive transfer of HCMV-specific T cells has been successfully used to prevent CMV disease after bone marrow transplantation for many years. In fact, the CD8 T cell response has been thought to be the most important effector response, with numerous reports focusing on specific T cell subsets recognizing select peptides in select human leukocyte antigen (HLA) contexts. However, it is becoming increasingly clear now that other cells, first and foremost CD4 T cells, but also gamma/delta (γ/δ) T cells and natural killer cells, are critically involved in the cellular immune response to HCMV. This commentary aims to provide a brief overview of the field.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.